Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Single dose of PF-07220060 as a Formulation · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Participants will receive PF-07220060 tablet by mouth |
| Cohort 2 | EXPERIMENTAL | Participants will receive PF-07220060 tablet by mouth |
| Cohort 3 | EXPERIMENTAL | Participants will receive PF-07220060 tablet by mouth |
| Cohort 4 | EXPERIMENTAL | Participants will receive PF-07220060 tablet by mouth |
| Cohort 5 | EXPERIMENTAL | Participants will receive PF-07220060 tablet by mouth |
| Cohort 6 | EXPERIMENTAL | Participants will receive PF-07220060 and Rabeprazole tablets by mouth |
| Cohort 7 | EXPERIMENTAL | Participants will receive PF-07220060 and Rabeprazole tablet by mouth |
| Cohort 8 | EXPERIMENTAL | Participants will receive PF-07220060 tablet by mouth |
| Name | Type | Description |
|---|---|---|
| Single dose of PF-07220060 as first Tablet Formulation | DRUG | A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions. |
| Single dose of PF-07220060 as second Tablet Formulation | DRUG | A single dose of PF-0720060 as the second Tablet Formulation administered under fasting conditions |
| Single dose of PF-07220060 as a Tablet Formulation | DRUG | A single dose of PF-07220060 as a tablet formulation administered under fed conditions |
| Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration | DRUG | A 2-treatment fixed sequence of single dose of PF-07220060 tablets under fasting conditions followed by a single dose of PF-07220060 tablets under Proton Pump Inhibitor (PPI) administration under fasting condition (following a 7 day oral rabeprazole tablets daily administration). |
| Single dose of PF-07220060 as third tablet formulation | DRUG | A 2-period randomized 2-sequence cross over of a single dose of PF-07220060 as first and third tablet formulation under fasting conditions with a 6-day washout in between them |
Inclusion Criteria: * Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring * BMI of 17.5-30.5 kg/m2; and a total body weight \>50 kg (110 lb). * Evidence of a personally sig...
PF-07220060 is being studied in healthy participants. It is an investigational small molecule in Phase 1 clinical development. The completed study evaluated multiple tablet forms of the study medicine in healthy adults to assess its formulation.
PF-07220060 is being developed by Pfizer, Inc. (NYSE: PFE). The company sponsored a Phase 1 clinical trial to evaluate the study medicine in healthy adult participants.
PF-07220060 is in Phase 1 clinical development. The single completed trial was a Phase 1 study in healthy participants. It is investigational and not yet approved for any use.
PF-07220060 has one completed clinical trial, NCT05923411, titled "A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults." This Phase 1 study enrolled 113 participants in the United States.
PF-07220060 as a Formulation refers to the study of different tablet forms of the drug PF-07220060. The clinical trial NCT05923411 evaluated multiple tablet formulations of the study medicine in healthy adults.